Kuros Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Kuros Biosciences has a total shareholder equity of CHF60.2M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF77.3M and CHF17.1M respectively.
Key information
0%
Debt to equity ratio
CHF 0
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 14.28m |
| Equity | CHF 60.18m |
| Total liabilities | CHF 17.13m |
| Total assets | CHF 77.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RHR's short term assets (CHF33.2M) exceed its short term liabilities (CHF12.2M).
Long Term Liabilities: 0RHR's short term assets (CHF33.2M) exceed its long term liabilities (CHF5.0M).
Debt to Equity History and Analysis
Debt Level: 0RHR is debt free.
Reducing Debt: 0RHR has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0RHR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0RHR has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 13.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 14:51 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Olav Zilian | Mirabaud Securities Limited |
| Dylan van Haaften | NIBC Bank N.V. |